Type:

Other

Description:

Physiology in Medicine review article Genetic and translational studies, as well as clinical trials, suggest that in a subgroup of patients, the pathobiology of severe asthma is mediated by immune pathways driven by T-helper 2 (Th2)–type CD4?? T cells, which produce a characteristic repertoire of interleukins (ILs), including IL-4, IL-5, and IL-13.The benefits of immune-modifier therapies targeting Th2-type cytokines, however, need to be weighed against the toxicities associated with inhibition of key biological pathways, as well as the expense of future medications. Therefore, future clinical trials need to clearly establish the efficacy and safety of biological modifiers of Th2 immune pathways before these approaches can enter routine clinical practice for the treatment of severe asthma.

Subjects:

  • Education > General

Education Levels:

    Keywords:

    Asthma,NSDL,NSDL_SetSpec_BEN,oai:nsdl.org:2200/20110722024309831T,Immune system,Life Science,Teacher-centered/traditional instruction,Education

    Language:

    English

    Access Privileges:

    Public - Available to anyone

    License Deed:

    Creative Commons Attribution Non-Commercial Share Alike

    Collections:

    None
    This resource has not yet been aligned.
    Curriki Rating
    'NR' - This resource has not been rated
    NR
    'NR' - This resource has not been rated

    This resource has not yet been reviewed.

    Not Rated Yet.

    Non-profit Tax ID # 203478467